Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pulike Biological EngineeringSHSE:603566 -2.47%69 5-Year Yield-on-Cost % is 13.76 as of Sep. 13, 2026, which is 270% above its 10-year median of 3.72. GuruFocus rates SHSE:603566 with a GF Score™ of 69/100 and a GF Value™ of ¥12.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 147 Biotechnology companies, Pulike Biological Engineering ranks better than 93.88% on this metric.
The historical rank and industry rank for Pulike Biological Engineering's 5-Year Yield-on-Cost % or its related term are showing as below:
SHSE:603566'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.3 Med: 3.72 Max: 14.89
Current: 13.76
During the past 13 years, Pulike Biological Engineering's highest Yield on Cost was 14.89. The lowest was 1.30. And the median was 3.72.
SHSE:603566's 5-Year Yield-on-Cost % is ranked better than 93.88% of 147
companies
in the Biotechnology industry
Industry Median: 1.66
vs SHSE:603566: 13.76
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Pulike Biological Engineering 5-Year Yield-on-Cost % Related Terms
SHSE:603566 vs VRTX, REGN, MRNA: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Pulike Biological Engineering's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulike Biological Engineering 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pulike Biological Engineering's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Pulike Biological Engineering's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Pulike Biological Engineering (SHSE:603566) has a 5-Year Yield-on-Cost % of 13.76 as of Sep. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pulike Biological Engineering and its competitors. This is 270% above median its historical median of 3.72. Over the past decade, Pulike Biological Engineering's 5-Year Yield-on-Cost % has ranged from 1.30 to 14.89. According to the industry distribution chart, Pulike Biological Engineering ranks #9 out of 147 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Pulike Biological Engineering's 5-Year Yield-on-Cost % too high?
Pulike Biological Engineering's current 5-Year Yield-on-Cost % of 13.76 is 270% above median its 10-year median of 3.72. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 14.89. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.66. Pulike Biological Engineering's value of 13.76 is 728.9% above this industry median. Based on the distribution chart, Pulike Biological Engineering ranks #9 out of 147 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pulike Biological Engineering has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pulike Biological Engineering's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pulike Biological Engineering ranks #9 out of 147 companies for 5-Year Yield-on-Cost %. This places Pulike Biological Engineering in the top 6% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 1.66. Pulike Biological Engineering's value of 13.76 is 728.9% above this benchmark. Historically, Pulike Biological Engineering's own 5-Year Yield-on-Cost % has ranged from 1.30 to 14.89 over the past decade. While the company's 10-year median is 3.72 vs. the industry median of 1.66, Pulike Biological Engineering has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.66, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulike Biological Engineering's current 5-Year Yield-on-Cost % of 13.76 is 728.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pulike Biological Engineering and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulike Biological Engineering's current 5-Year Yield-on-Cost % is 13.76, which is 270% above median its own 10-year median of 3.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulike Biological Engineering stock overvalued right now?
Based on GuruFocus' analysis, Pulike Biological Engineering (SHSE:603566) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥12.98, compared to a current price of ¥10.27 — trading 20.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 13.76, which is 270% above median its 10-year median of 3.72 and 728.9% above the Biotechnology industry median of 1.66. Pulike Biological Engineering's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Pulike Biological Engineering (SHSE:603566), the current 5-Year Yield-on-Cost % is 13.76 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulike Biological Engineering (SHSE:603566) Overvalued in 2026?
Based on GuruFocus' analysis, Pulike Biological Engineering stock appears to be undervalued.
The current stock price of ¥10.27 is trading 20.9% below its estimated GF Value™ of ¥12.98.
GuruFocus considers Pulike Biological Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:603566:
5-Year Yield-on-Cost %: 13.76 (270% above median its 10-year median of 3.72)
GF Value™: ¥12.98 vs. price of ¥10.27 (20.9% below fair value)
Industry Position: 728.9% above the Biotechnology median (#9 of 147)
No single metric tells the full story. See the SHSE:603566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603566 has been successfully added to your 
